کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5973955 | 1576199 | 2013 | 6 صفحه PDF | دانلود رایگان |
BackgroundDrug-eluting stents (DES) are routinely used in complex patients, but the impact of 1st- versus 2nd-generation DES on clinical outcomes has not been well described. This study aimed to assess the efficacy and safety of 2nd-generation (everolimus-eluting) DES compared to 1st-generation (sirolimus- and paclitaxel-eluting) DES in a selected, higher-risk population with complex clinical and angiographic features.MethodsThe study included 5693 consecutive patients with the presence of â¥Â 1 predefined complex clinical and angiographic characteristic treated with either generation DES. Using propensity score matching, the clinical outcomes of 1076 patients treated with 2nd-generation DES were compared with the outcomes of a matched population treated with 1st-generation DES over 1-year follow-up.ResultsAfter matching, baseline clinical and angiographic characteristics were similar between groups. At 1-year follow-up, the rate of major adverse cardiac events was 9.4% with 2nd-generation DES and 11.3% with 1st-generation DES (p = 0.16). There were no significant differences in the rates of death (3.2 vs. 4.0%, p = 0.30), myocardial infarction (1.6 vs. 1.3%, p = 0.57), target vessel revascularization (5.9 vs. 7.3%, p = 0.17) or target lesion revascularization (4.4 vs. 5.0%, p = 0.50). Definite stent thrombosis was less frequent with 2nd-generation DES (0.1 vs. 0.8%, p = 0.011), as was definite or probable stent thrombosis (0.7 vs. 1.6%, p = 0.040).ConclusionIn this propensity score matched patient population with complex features undergoing percutaneous coronary intervention, the use of 2nd-generation DES was associated with lower rates of stent thrombosis, and similar 1-year major adverse cardiac events compared to 1st-generation DES.
Journal: International Journal of Cardiology - Volume 170, Issue 1, 5 December 2013, Pages 43-48